The massive potential dilution from the resale registration, combined with the company's precarious cash position and pre-revenue status, creates significant downside risk. Monitor for any exercise of the Series C warrants (which would provide cash to the company) and for any news on clinical trial initiation, as the company plans to submit a CTA in Q4 2026.
Executive Summary
Propanc Biopharma filed an S-1 registration statement for the resale of up to 6,500,000 shares of common stock by Hexstone Capital LLC, the selling stockholder. The shares are issuable upon conversion of Series C Preferred Stock and exercise of warrants. The company is a pre-revenue, development-stage biopharmaceutical firm with a going concern qualification, an accumulated deficit of $144.5M, and no revenue for FY2026.
Key Facts
- S-1 registers up to 6,500,000 shares of common stock for resale by Hexstone Capital LLC, representing ~66% of current shares outstanding (9,831,116 as of Oct 1, 2026).
- Company has no revenue, net loss of $18.86M for FY2026, accumulated deficit of $144.48M, and a going concern qualification.
- Cash at June 30, 2026 was only $832,006; net cash used in operations was $5.68M for FY2026.
- Lead product candidate PRP is still in preclinical development; no clinical trials have been initiated.
- The Series C Preferred Stock conversion price floor was adjusted to $0.05 per share, enabling massive potential dilution.
- Company is in default on ~$212,000 in loans payable as of the filing date.
Financial Impact
Potential dilution of up to 66% from the resale of 6.5M shares; no proceeds to the company from the resale. The company's cash burn of $5.68M in FY2026 far exceeds its $832K cash balance.
Risk Factors
- Massive dilution from the resale of up to 6.5M shares (66% of current float) by Hexstone Capital.
- Going concern risk: only $832K cash with $5.68M annual cash burn; substantial doubt about ability to continue.
- Pre-revenue, preclinical-stage pipeline with no guarantee of clinical success or regulatory approval.
- Potential Nasdaq delisting risk due to low stock price ($0.501 as of Oct 1, 2026) and prior non-compliance with minimum bid price requirement.
- Significant debt defaults and reliance on dilutive convertible financing.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-045770 |
| Exhibit: ex107.htm | 0001493152-26-045770 |
| Exhibit: ex5-1.htm | 0001493152-26-045770 |
| Exhibit: ex23-1.htm | 0001493152-26-045770 |
| Document: 0001493152-26-045770-index-headers.html | 0001493152-26-045770 |
| Document: 0001493152-26-045770-index.html | 0001493152-26-045770 |
| Document: 0001493152-26-045770.txt | 0001493152-26-045770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | — |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | — |
Sep 29, 2026 27d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | — |
Aug 18, 2026 9w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | — |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | — |
May 19, 2026 22w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | — |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | — |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | — |
Apr 21, 2026 26w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | — |
Mar 24, 2026 30w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers